Latest Medicinal Cannabis News

Wellnex Life reported an 18.2% sales decline in Q1 FY26 amid delayed IP licensing revenue and increased costs, while securing new debt facilities and exiting the medicinal cannabis segment.

ECS Botanics reports a positive cash flow milestone in Q1 FY26, driven by strong direct-to-consumer sales and operational efficiencies, while preparing for a European market debut.

Cann Group Limited has extended the expiry of its NAB debt facilities by two weeks, providing a brief but vital window to advance its refinancing plans.

Bod Science Limited has reported a notable profit turnaround for FY2025, driven by medicinal cannabis sales growth, while navigating a complex Deed of Company Arrangement and a proposed backdoor listing with Biortica Agrimed Limited.

Bioxyne Limited has secured import permits and purchase orders worth A$5.1 million for medical cannabis in Germany, signaling strong early traction in a key European market.

Cann Group Limited has disclosed a late payment of over $1.37 million in interest and facility fees to National Australia Bank, which has issued a non-waiver letter but is holding off on immediate action. The company is actively negotiating financing arrangements and plans to update the market by the end of September 2025.

Althea Group Holdings reports a significant reduction in losses for FY25, driven by asset sales and strategic refocus on North American THC beverages. The company completed a $4 million capital raise and navigated leadership changes amid subsidiary liquidations.

Cann Group Limited reported a 34% rise in dried flower production and doubled Botanitech brand flower sales in FY25, while cutting operating expenses by 35%. The company is targeting an EBITDA-positive FY26 amid ongoing debt restructuring.

Cann Group Limited reported a significant 56% reduction in net loss for FY25, driven by cost cuts and strong growth in dried flower sales, even as revenue declined due to shifting product preferences. The company faces going concern challenges but is actively pursuing debt refinancing and operational improvements.

Bioxyne Limited delivered a record FY25 with $30.4 million revenue, driven by Australian market growth and new European contracts. The company projects revenue up to $75 million in FY26, fueled by expanded production and international market entries.

ECS Botanics reports a 5% revenue dip to $19.5 million in FY25 but sees strong B2C growth and record harvest volumes, offset by non-cash impairments.

Bioxyne Limited reports a remarkable financial turnaround for FY2025, driven by a 217% revenue surge and its first significant profit, underpinned by expanded medicinal cannabis manufacturing and new supply contracts.